Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Evolva Holding S.A.. (12/22/14). "Press Release: Evolva Completes Share Sale Related to Allylix acquisition". Reinach.

Organisations Organisation Evolva Holding SA (SIX: EVE)
  Group Evolva (Group)
  Organisation 2 Allylix Inc.
  Group Evolva (Group)
Products Product industrial biotechnology
  Product 2 investment banking
Index term Index term Allylix–Evolva: investment, 201411–201412 acquisition merger for 46m new Evolva shares representing 14.1% post-merger share
Persons Person Hansen, Jakob Dynnes (Acesion Pharma 201611– CFO before Evolva + Nuevolution + Zealand Pharma + Novo Nordisk)
  Person 2 Goldsmith, Neil (Evolva –200910–201707 CEO STEPPED DOWN 7/17)
     


Evolva Holding SA (SIX: EVE), has completed the placing of all shares earmarked to satisfy certain liabilities and transaction expenses related to the Allylix acquisition, as announced on 16 December 2014. A total of 6.1 million shares were sold between 16 and 19 December. One Swiss investment fund acquired a block of five million shares. The transaction has no impact on the number of outstanding Evolva shares.

Jakob Dynnes Hansen, Evolva CFO, commented, “This placing went faster than we had expected and is a vote of confidence from the investment community.”


About Evolva

Evolva is a pioneer and global leader in sustainable, fermentation-based approaches to ingredients for health, wellness and nutrition. Evolva’s products include stevia, vanilla, saffron and resveratrol. As well as developing its own proprietary ingredients, Evolva also deploys its technology for partners, providing them with a competitive edge and sharing in the returns they make. For more information see www.evolva.com. Questions about our fermentation approach? Have a look at our video.


Contact Details

Evolva
Neil Goldsmith, CEO Jakob Dynnes Hansen, CFO Paul Verbraeken, IR
neilg@evolva.com jakobdh@evolva.com paulv@evolva.com
+ 41 61 485 2005 + 41 61 485 2034 + 41 61 485 2035


This press release does not constitute an offer or invitation to sell, or a solicitation of an offer to buy shares in Evolva Holding SA (the “Shares”) in any jurisdiction, nor shall it (or any part of it) or the fact of the listing of the new Shares, form the basis of, or be relied on in connection with, any contract therefore. This press release does not constitute (i) an offering prospectus, and no securities will be offered or sold directly or indirectly to any person or the public within the meaning of article 652a of the Swiss Code of Obligations, (ii) a listing prospectus within the meaning of the SIX Swiss Exchange Listing Rules, nor (iii) a prospectus within the meaning of the EC Directive 2003/71/EC of the European Parliament and of the Council dated November 4, 2003 (the “Prospectus Directive”). This press release is only addressed to, and is only directed at, qualified investors in any member state of the European Economic Area within the meaning of the Prospectus Directive. In addition, the securities referenced herein have not been and are not intended to be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States of America absent registration under that act or an available exemption from registration requirements under that act. The listing prospectus dated 16 December 2014 is the sole and decisive document for the listing of the New Shares on the SIX Swiss Exchange. Copies of the Listing Prospectus are available free of charge at Evolva Holding SA, Duggingerstrasse 23, CH-4153 Reinach (telephone: +41 61 485 2006, facsimile: +41 61 485 2001, e-mail: paulv@evolva.com).


This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Evolva (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture BioM Forum Translational Medicine 2018 Würzburg Germany 600x60px




» top